The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients ...
Bristol-Myers Squibb has phase 3 data from its deucravacitinib psoriasis pill, showing it outperformed Amgen’s rival Otezla ... s American Academy of Dermatology virtual meeting.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback